Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Promising Results for GXB's MCL Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Promising Results for GXB’s MCL Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gemin X Biotechnologies achieved positive preclinical study results evaluating GX15-070 both as a monotherapy and in combination with the proteasome inhibitor Velcade for the treatment of mantle cell lymphoma (MCL). The data demonstrated that GX15-070 induced apoptosis and exhibited synergistic effects with Velcade.

In the preclinical study, GX15-070 as a single agent induced apoptosis in vitro in MCL cells lines and in primary cells from MCL patients, with 9 out of 12 patient samples showing strong sensitivity to GX15-070. GX15-070 was also evaluated in combination with Velcade, which has shown promising results in MCL treatment but can also induce the intracellular accumulation of the MCL-1, leading to resistance. The combination of GX15-070 and Velcade resulted in a synergistic effect, allowing a reduction in the dose of Velcade required to kill cancer cells. No cytotoxic affects were observed in non-cancerous cell lines, suggesting that GX15-070 may represent an attractive new investigational therapeutic option for the treatment of MCL.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters